Tillotts Pharma Report issue

Contributed to NME For profit Phase 1 Phase 3 Phase 4
Founded: London United Kingdom (1955)
Status: Acquired by Medeva (1995) → now UCB (2004)

Organization Overview

First Clinical Trial
2002
NCT00074542
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tillotts Pharma AG

Active Ingredients

Drugs in Phase 4 Trials (2)

amitriptyline (elavil) (1 trial)

mesalamine (rowasa) (6 trials)

Drugs in Phase 3 Trials (2)

mesalazine (4 trials)

omega-3-carboxylic acids (epanova) (2 trials)

Drugs in Phase 1 Trials (1)

metronidazole (flagyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 3)

Colitis, Ulcerative (Phase 3)

Crohn Disease (Phase 3)

Diarrhea (Phase 4)

Irritable Bowel Syndrome (Phase 4)

Syndrome (Phase 4)

Ulcer (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 12
  • # of Trial APIs: 5